XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10th through 13th, 2022. At the conference, Dr. Allen Davidoff, XORTX’s CEO will provide an update on the Company with an overview of Company progress and planned activities for 2022.
A webcast of the pre-recorded presentation is available at the below link utilizing passcode J1yP%=?d.
Dr. Allen Davidoff, CEO of XORTX stated, “We are pleased that XORTX has been invited to present at the H.C. Wainwright BioConnect 2022 meeting and during the virtual JP Morgan meeting week. This presentation represents an opportunity to continue outreach to a broad spectrum of global investors and potential pharmaceutical company partners. This presentation kicks off a busy week of meetings associated with the JP Morgan virtual conference and business development and investor relations activities.”
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX Therapeutics is available at www.xortx.com.
For further information, please contact:
Allen Davidoff, CEO | Nick Rigopulos, Director of Communications |
This email address is being protected from spambots. You need JavaScript enabled to view it. or +1 403 455 7727 | This email address is being protected from spambots. You need JavaScript enabled to view it. or +1 617 901 0785 |
The TSX Venture Exchange and Nasdaq have neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Last Trade: | US$3.60 |
Daily Change: | -0.20 -5.26 |
Daily Volume: | 58,877 |
Market Cap: | US$10.440M |
March 19, 2024 January 03, 2024 January 02, 2024 August 29, 2023 |
LithiumBank Resources is creating an opportunity to participate in the future of clean-tech energy. The company's strategy is to acquire claims in known lithium high grade hot spots with existing wells and infrastructure...
CLICK TO LEARN MOREElse Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS